Latest Fairmount Funds Management LLC Stock Portfolio
$1.38Billion | No. of Holdings #12
Fairmount Funds Management LLC Performance
2026 Q1+18.26%
YTD+18.26%
2025+70.58%
About Fairmount Funds Management LLC and 13F Hedge Fund Stock Holdings
On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Fairmount Funds Management LLC reported an equity portfolio of $1.4 Billions as of 31 Mar, 2026. <br><br> The top stock holdings of Fairmount Funds Management LLC are GLTO, , COGT. The fund has invested 16.3% of it's portfolio in DAMORA THERAPEUTICS INC and 15.4% of portfolio in DIANTHUS THERAPEUTICS INC. <br><br> The fund managers got completely rid off NUVALENT INC (NUVL) and KINIKSA PHARMACEUTICALS INTL stocks. They significantly reduced their stock positions in APOGEE THERAPEUTICS INC and COGENT BIOSCIENCES INC (COGT). Fairmount Funds Management LLC opened new stock positions in DAMORA THERAPEUTICS INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to DIANTHUS THERAPEUTICS INC.
Fairmount Funds Management LLC Equity Portfolio Value
Last Reported on: 15 May, 2026
$1.38Billion
as of May 15, 2026Fairmount Funds Management LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Fairmount Funds Management LLC made a return of 18.26% in the last quarter. In trailing 12 months, it's portfolio return was 135.55%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| damora therapeutics inc | 225,667,000 |
New stocks bought by Fairmount Funds Management LLC
Additions
| Ticker | % Inc. |
|---|---|
| dianthus therapeutics inc | 18.72 |
| zenas biopharma inc | 6.79 |
Additions to existing portfolio by Fairmount Funds Management LLC
Reductions
| Ticker | % Reduced |
|---|---|
| apogee therapeutics inc | -85.42 |
| enliven therapeutics inc | -50.00 |
| cogent biosciences inc | -38.87 |
Fairmount Funds Management LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| kiniksa pharmaceuticals intl | -54,437,100 |
| nuvalent inc | -73,185,600 |
Fairmount Funds Management LLC got rid off the above stocks
Sector Distribution
Fairmount Funds Management LLC has about 57.4% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 57.4 |
| Others | 42.6 |
Market Cap. Distribution
Fairmount Funds Management LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- MID-CAP
- NANO-CAP
- SMALL-CAP
| Category | % |
|---|---|
| UNALLOCATED | 42.6 |
| MID-CAP | 35.5 |
| NANO-CAP | 16.3 |
| SMALL-CAP | 4.6 |
Stocks belong to which Index?
About 25.5% of the stocks held by Fairmount Funds Management LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 74.5 |
| RUSSELL 2000 | 25.5 |
| Top 5 Winners (%) | % | |
|---|---|---|
enliven therapeutics inc | 115.9 % | |
dianthus therapeutics inc | 88.3 % | |
oruka therapeutics inc | 61.8 % | |
crescent biopharma inc. | 54.9 % | |
| AGLE | spyre therapeutics inc | 54.0 % |
Fairmount Funds Management LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Fairmount Funds Management LLC
Fairmount Funds Management LLC has 12 stocks in it's portfolio. VRDN proved to be the most loss making stock for the portfolio. was the most profitable stock for Fairmount Funds Management LLC last quarter.
$1.38BTotal Value
14.00Positions
15 May, 2026Last Reported
| Expand | Holdingsorted ascending | % Portfolio | Shares Held | $ Value | % Change |
|---|---|---|---|---|---|
 Spyre Therapeutics Inc Fairmount Funds Management LLC's holding in Spyre Therapeutics Inc over time | 14.64% | 4,018,100 | $202.67M 14.64% | 0%unchanged 0 percentunchanged | |
 Jade Biosciences Inc Fairmount Funds Management LLC's holding in Jade Biosciences Inc over time | 4.62% | 4,553,490 | $63.98M 4.62% | 0%unchanged 0 percentunchanged | |
 Cogent Biosciences Inc Fairmount Funds Management LLC's holding in Cogent Biosciences Inc over time | 15.3% | 5,503,420 | $211.83M 15.3% | 38.87%decreased 38.87 percentreduced | |
 Damora Therapeutics Inc Fairmount Funds Management LLC's holding in Damora Therapeutics Inc over time | 16.3% | 8,713,000 | $225.67M 16.3% | Newnew position | |
 Inhibikase Therapeutics Inc Fairmount Funds Management LLC's holding in Inhibikase Therapeutics Inc over time | 1.05% | 8,625,000 | $14.49M 1.05% | 0%unchanged 0 percentunchanged | |
 Nuvalent Inc Nuvalent IncNUVL Fairmount Funds Management LLC's holding in Nuvalent Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Viridian Therapeutics Inc Fairmount Funds Management LLC's holding in Viridian Therapeutics Inc over time | 5.53% | 3,914,460 | $76.57M 5.53% | 0%unchanged 0 percentunchanged | |
Com Dianthus Therapeutics IncDianthus Therapeutics Inc | 15.38% | 2,537,190 | $212.92M 15.38% | 18.72%increased 18.72 percentadded | |
Com Oruka Therapeutics IncOruka Therapeutics Inc | 13.13% | 3,705,260 | $181.74M 13.13% | 0%unchanged 0 percentunchanged | |
Com Enliven Therapeutics IncEnliven Therapeutics Inc | 5.26% | 1,855,640 | $72.74M 5.26% | 50%decreased 50 percentreduced | |
Com Crescent Biopharma Inc.Crescent Biopharma Inc. | 3.65% | 2,747,870 | $50.48M 3.65% | 0%unchanged 0 percentunchanged | |
Com Zenas Biopharma IncZenas Biopharma Inc | 3.33% | 2,359,020 | $46.12M 3.33% | 6.79%increased 6.79 percentadded | |
Com Apogee Therapeutics IncApogee Therapeutics Inc | 1.82% | 298,647 | $25.14M 1.82% | 85.42%decreased 85.42 percentreduced | |
Ord Shs Cl A Kiniksa Pharmaceuticals IntlKiniksa Pharmaceuticals Intl | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |